Eruptive pseudoangiomatosis: report of an adult case and unifying hypothesis of the pathogenesis of paediatric and adult cases.
One month after the onset of immunosuppressive treatment with corticosteroids and mycophenolate mofetil for a newly diagnosed pemphigus vulgaris, a 50-year-old female patient developed a new eruption clinically and histomorphologically consistent with eruptive pseudoangiomatosis (EP). Its self-limited course further confirmed this diagnosis. Although initially described as a paediatric eruption, meanwhile more adult cases of EP (30 out of a total of 53 cases identified by a Medline search) are reported in the literature. The review of adult cases of EP disclosed some common clinical and epidemiological characteristics: adult EP cases tend to cluster in the Mediterranean region of Europe, develop during the summer months, sometimes in the form of limited micro-epidemics, affect immunocompromised individuals and have lesions confined to the exposed skin sites. These characteristics, together with the exanthematic nature of the disease in children, point to some vector-transmitted infectious agent as the cause of this probably underdiagnosed disease.
Chaniotakis
I
I
Department of Skin and Venereal Diseases, University of Ioannina Medical School, Ioannina, Greece.
Nomikos
K
K
Gamvroulia
C
C
Zioga
A
A
Stergiopoulou
C
C
Bassukas
I D
ID
D000798:Angiomatosis / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D001707:Biopsy, Needle; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016867:Immunocompromised Host; D007150:Immunohistochemistry; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives; D010392:Pemphigus / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology*; D018570:Risk Assessment; D012720:Severity of Illness Index; D017445:Skin Diseases, Vascular / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D016896:Treatment Outcome
D009173:Mycophenolic Acid; D008775:Methylprednisolone